Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer
Takahiro Tsujikawa(Oregon Health & Science University), Dung T. Le(Johns Hopkins University), Michael Considine(Sidney Kimmel Comprehensive Cancer Center), Lisa M. Coussens(Oregon Health & Science University), Elana J. Fertig(Bloomberg (United States)), Ludmila Danilova(Bloomberg (United States)), Daniel A. Laheru(Bloomberg (United States)), George A. Fisher(Stanford University), Robert H. Vonderheide(University of Pennsylvania), Elizabeth A. Sugar(Johns Hopkins University), Elizabeth M. Jaffee(Bloomberg (United States)), Beth Onners(Sidney Kimmel Comprehensive Cancer Center), Andrew H. Ko(University of California, San Francisco), Julie M. Nauroth(Sidney Kimmel Comprehensive Cancer Center), Margaret A. Tempero(University of California, San Francisco), Annie A. Wu(Johns Hopkins University), Todd S. Crocenzi(Providence Portland Medical Center), Dirk G. Brockstedt(Rapt Therapeutics (United States)), Kim A. Reiss(University of Pennsylvania), Robert A. Anders(Sidney Kimmel Comprehensive Cancer Center), Jennifer N. Durham(Sidney Kimmel Comprehensive Cancer Center)
Cited by 151
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
|Cancer Cell|2012|4.7k